Skip to content
Roboearth – Lifestyle
Author:
Milu
Egret Therapeutics Signs Memorandum of Understanding with Genexine Toward Full Ownership of Lead PD-1 Agonist Asset GX-P1 (EGT-101)
March 16, 2026